Potent CSF-1R inhibitor (IC50 = 20 nM). Reduces system and local macrophages accumulation without affecting Gr-1+ myeloid derived suppressor cells in the B16F10 mouse melanoma model. Promotes tumor growth control in combination with CD8 T-cell immunotherapy and improces adoptive cell therapy efficacy in the BRAFV600E-driven mouse melanoma model. Orally bioavailable. Recently reported to eliminate brain microglial temporarily and recoverably in adult mice.
Solubility & Handling
Storage instructions
-20°C
Solubility overview
Soluble in DMSO (100 mM)
Important
This product is for RESEARCH USE ONLY and is not intended for therapeutic or diagnostic use. Not for human or veterinary use
Pexidartinib, a Novel Small Molecule CSF-1R Inhibitor in Use for Tenosynovial Giant Cell Tumor: A Systematic Review of Pre-Clinical and Clinical Development.
Benner B et al (2020) Drug design, development and therapy 14 : 1693-1704